|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
|
US7883704B2
(en)
|
1999-03-25 |
2011-02-08 |
Abbott Gmbh & Co. Kg |
Methods for inhibiting the activity of the P40 subunit of human IL-12
|
|
EP1268550A2
(en)
*
|
2000-03-17 |
2003-01-02 |
Boehringer Ingelheim Pharma KG |
Human fap-alpha-specific antibodies
|
|
PE20021080A1
(es)
*
|
2001-04-12 |
2003-02-12 |
Boehringer Ingelheim Int |
Un anticuerpo especifico fapo bibh1 en el tratamiento del cancer
|
|
EP2365004B1
(en)
*
|
2002-06-21 |
2016-01-06 |
Johns Hopkins University School of Medicine |
Membrane associated tumor endothelium markers
|
|
DK1534335T4
(en)
*
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
|
US8044180B2
(en)
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8193318B2
(en)
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
|
US7384744B2
(en)
|
2002-11-29 |
2008-06-10 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
CA2512729C
(en)
|
2003-01-09 |
2014-09-16 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
|
DK1594955T3
(da)
*
|
2003-02-14 |
2012-06-25 |
Biogen Idec Inc |
Ekspressionskassette og vektor til transient eller stabil ekspression af eksogene molekyler
|
|
CA2565874C
(en)
|
2004-05-10 |
2017-10-03 |
Macrogenics, Inc. |
Humanized fc.gamma.riib-specific antibodies and methods of use thereof
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
PL2573114T3
(pl)
|
2005-08-10 |
2016-10-31 |
|
Identyfikacja i inżynieria przeciwciał z wariantami regionów FC oraz sposoby ich stosowania
|
|
CA2631184A1
(en)
*
|
2005-11-28 |
2007-05-31 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
|
EP1806365A1
(en)
*
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
WO2008105886A2
(en)
|
2006-05-26 |
2008-09-04 |
Macrogenics, Inc. |
HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
ES2599319T3
(es)
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
|
|
WO2008002933A2
(en)
|
2006-06-26 |
2008-01-03 |
Macrogenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
|
KR20090100461A
(ko)
|
2007-01-16 |
2009-09-23 |
아보트 러보러터리즈 |
건선의 치료방법
|
|
RU2476442C2
(ru)
|
2007-03-29 |
2013-02-27 |
Эббот Лэборетриз |
Кристаллические антитела против il-12 человека
|
|
ES2840725T3
(es)
*
|
2007-08-20 |
2021-07-07 |
Glaxo Group Ltd |
Procedimiento de producción
|
|
CN101896818B
(zh)
*
|
2007-12-10 |
2016-01-20 |
霍夫曼-拉罗奇有限公司 |
作为癌症的标记物的Seprase
|
|
EP2071337A1
(en)
*
|
2007-12-10 |
2009-06-17 |
F.Hoffmann-La Roche Ag |
Seprase as a marker for cancer
|
|
CN101896817A
(zh)
*
|
2007-12-10 |
2010-11-24 |
霍夫曼-拉罗奇有限公司 |
用于结直肠癌的标记物组
|
|
WO2009117289A2
(en)
|
2008-03-18 |
2009-09-24 |
Abbott Laboratories |
Methods for treating psoriasis
|
|
WO2009123894A2
(en)
|
2008-04-02 |
2009-10-08 |
Macrogenics, Inc. |
Her2/neu-specific antibodies and methods of using same
|
|
ES2589912T3
(es)
|
2008-04-02 |
2016-11-17 |
Macrogenics, Inc. |
Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos
|
|
SG179135A1
(en)
|
2009-09-14 |
2012-05-30 |
Abbott Lab |
Methods for treating psoriasis
|
|
JP5898082B2
(ja)
|
2009-10-07 |
2016-04-06 |
マクロジェニクス，インコーポレーテッド |
フコシル化程度の変更により改良されたエフェクター機能を示すＦｃ領域含有ポリペプチドおよびその使用法
|
|
EP2542256B1
(en)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
CA2806021C
(en)
*
|
2010-08-13 |
2019-05-21 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
SG192673A1
(en)
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
WO2014004639A1
(en)
|
2012-06-26 |
2014-01-03 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
|
CN103267852B
(zh)
*
|
2013-05-15 |
2015-03-25 |
中国医学科学院北京协和医院 |
成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
|
|
WO2015006555A2
(en)
|
2013-07-10 |
2015-01-15 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
GB201402006D0
(en)
|
2014-02-06 |
2014-03-26 |
Oncomatryx Biopharma S L |
Antibody-drug conjugates and immunotoxins
|
|
RS59700B1
(sr)
*
|
2014-03-26 |
2020-01-31 |
Univ Wuerzburg J Maximilians |
Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera
|
|
CN105646710B
(zh)
*
|
2014-11-17 |
2020-08-25 |
四川科伦博泰生物医药股份有限公司 |
一种全人源化抗vegfr-2单克隆抗体及其制备方法
|
|
US10526413B2
(en)
|
2015-10-02 |
2020-01-07 |
Hoffmann-La Roche Inc. |
Bispecific antibodies specific for OX40
|
|
WO2017132615A1
(en)
*
|
2016-01-27 |
2017-08-03 |
Sutro Biopharma, Inc. |
Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
|
|
GEP20227398B
(en)
|
2016-04-15 |
2022-07-25 |
Macrogenics Inc |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
|
|
AU2017290828A1
(en)
|
2016-06-30 |
2019-01-24 |
Virogin Biotech Canada Ltd |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ |
新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
|
|
CN116474108A
(zh)
*
|
2016-12-14 |
2023-07-25 |
普渡研究基金会 |
成纤维细胞活化蛋白(fap)-靶向成像和治疗
|
|
EP3731850A4
(en)
|
2017-12-29 |
2021-12-01 |
Oncorus, Inc. |
ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
|
|
CN110526979A
(zh)
*
|
2018-05-25 |
2019-12-03 |
深圳宾德生物技术有限公司 |
靶向fap的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
|
|
CN110526991A
(zh)
*
|
2018-05-25 |
2019-12-03 |
深圳宾德生物技术有限公司 |
靶向fap的嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用
|
|
CN109053893B
(zh)
*
|
2018-08-15 |
2021-03-30 |
智享生物(苏州)有限公司 |
一种抗d-二聚体单克隆抗体及其制备方法
|
|
CN112972675A
(zh)
*
|
2018-09-07 |
2021-06-18 |
上海君实生物医药科技股份有限公司 |
抗pd-1抗体在治疗肿瘤中的用途
|
|
CN111944055B
(zh)
*
|
2019-05-16 |
2022-08-02 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的融合蛋白
|
|
EP3763726A1
(en)
|
2019-07-08 |
2021-01-13 |
3B Pharmaceuticals GmbH |
Compounds comprising a fibroblast activation protein ligand and use thereof
|
|
FI3997103T3
(fi)
|
2019-07-08 |
2025-02-03 |
3B Pharmaceuticals Gmbh |
Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö
|
|
JP7801207B2
(ja)
|
2019-07-08 |
2026-01-16 |
３ベー ファーマシューティカルズ ゲーエムベーハー |
線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
|
|
US12371491B2
(en)
|
2019-09-03 |
2025-07-29 |
Bio-Thera Solutions, Ltd. |
Anti-TIGIT immunosuppressant and application thereof
|
|
CN113512116B
(zh)
*
|
2020-04-10 |
2022-09-20 |
苏州普乐康医药科技有限公司 |
一种抗igf-1r抗体及其应用
|
|
KR102363980B1
(ko)
*
|
2020-04-13 |
2022-02-15 |
전남대학교산학협력단 |
전이성 뇌종양의 진단 또는 예후 분석용 바이오마커 및 이를 이용한 진단방법
|
|
WO2021219092A1
(en)
*
|
2020-04-30 |
2021-11-04 |
I-Mab Biopharma Co., Ltd. |
Pharmaceutical compositionscontaining anti-cd47 antibodies
|
|
WO2021236658A1
(en)
|
2020-05-19 |
2021-11-25 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
|
CN112540176B
(zh)
*
|
2020-07-08 |
2021-09-28 |
深圳霁因生物医药转化研究院 |
用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质
|
|
IL300534A
(en)
*
|
2020-08-11 |
2023-04-01 |
Kanaph Therapeutics Inc |
A fusion protein containing 12-il and an anti-fap antibody, and its use
|
|
EP4050018A1
(en)
|
2021-01-07 |
2022-08-31 |
3B Pharmaceuticals GmbH |
Compounds comprising a fibroblast activation protein ligand and use thereof
|
|
IL303925A
(en)
|
2021-01-07 |
2023-08-01 |
3B Pharmaceuticals Gmbh |
Compounds comprising a fibroblast activation protein ligand and use thereof
|
|
WO2023031644A1
(en)
|
2021-08-31 |
2023-03-09 |
Full-Life Technologies Limited |
Anti-fibroblast activation protein (fap) single domain antibodies and uses thereof
|
|
CN118974258A
(zh)
*
|
2021-12-30 |
2024-11-15 |
乐普创一生物科技（上海）有限公司 |
抗fap-alpha的人源抗体
|
|
EP4578877A1
(en)
|
2022-08-03 |
2025-07-02 |
Nanjing Leads Biolabs Co., Ltd. |
Antibody fusion protein targeting fap and tgf-beta, and use thereof
|
|
CN120112308A
(zh)
|
2022-10-07 |
2025-06-06 |
吉尼松公司 |
使用抗fap car-t细胞免疫治疗骨骼肌病
|
|
CN116589566A
(zh)
*
|
2022-11-18 |
2023-08-15 |
昆明医科大学第一附属医院 |
一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
|
|
CN120309735A
(zh)
*
|
2024-01-15 |
2025-07-15 |
迈威(上海)生物科技股份有限公司 |
重组抗fap抗体及其应用
|
|
CN118496382B
(zh)
*
|
2024-05-22 |
2025-01-07 |
山东第一医科大学附属省立医院(山东省立医院) |
一种靶向fap的嵌合抗原受体、car-t细胞及其在肝纤维化中的应用
|
|
CN118812715A
(zh)
*
|
2024-07-02 |
2024-10-22 |
国睿(广州)生物科技有限公司 |
一种靶向成纤维活化蛋白α的纳米抗体及其应用
|
|
CN119265201A
(zh)
*
|
2024-08-23 |
2025-01-07 |
中国人民解放军海军军医大学第一附属医院 |
编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途
|